Loading...
•
Dec 31, 2024
ACADIA Q4 2024 Earnings Report
Acadia Pharmaceuticals reported strong fourth quarter and full year 2024 financial results, with record revenues for both NUPLAZID and DAYBUE, and provided optimistic 2025 guidance.
Key Takeaways
Acadia Pharmaceuticals closed 2024 with record revenues for both NUPLAZID and DAYBUE in the fourth quarter, contributing to a 32% revenue growth for the full year. The company reported a net income of $143.7 million for Q4 2024, a significant increase from the previous year, and provided strong revenue guidance for 2025.
Total revenues for the fourth quarter of 2024 were $259.6 million.
Net income for the fourth quarter of 2024 was $143.7 million, or $0.86 per common share.
NUPLAZID net product sales increased by 13% to $162.9 million in Q4 2024 compared to Q4 2023.
DAYBUE net product sales increased by 11% to $96.7 million in Q4 2024 compared to Q4 2023.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.comDAYBUE Sales Revenue
CapyFin.com Forward Guidance
Acadia Pharmaceuticals provided strong financial guidance for the full year 2025, anticipating continued growth for both NUPLAZID and DAYBUE, along with strategic investments in commercial expansion and pipeline advancement.
Positive Outlook
- Total revenues (U.S. only) are projected to be between $1.03 billion and $1.095 billion.
- NUPLAZID net product sales are expected to be in the range of $650 million to $690 million.
- DAYBUE net product sales (U.S. only) are expected to be in the range of $380 million to $405 million.
- Continued investment in consumer activation to drive market share expansion for NUPLAZID in the US.
- Expansion of DAYBUE field force in the US and building of EU commercial team for potential trofinetide launch next year.
Challenges Ahead
- R&D expense is projected to be in the range of $310 million to $330 million, indicating increased investment.
- SG&A expense is projected to be in the range of $535 million to $565 million, reflecting increased marketing and commercialization costs.
- Topline readouts for later-stage pipeline programs are not expected until the first half of 2026.
- Last patient enrollment for COMPASS PWS Phase 3 study is not expected until Q4 2025.
- Last patient enrollment for RADIANT Phase 2 study is not expected until Q1 2026.